Canada Markets closed

Vaxil Bio Ltd. (VXL.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.0950-0.0050 (-5.00%)
At close: 3:13PM EDT
Sign in to post a message.
  • S
    Sam
    The new preclinical trials for cancer immunotherapy announced today is good news.

    Then again where is the funding news ? How will they pay for trials when they barely had enough to pay for the COVID ongoing trials ?
  • S
    Sammy Z
    Their is obviously something brewing, over 1500 trying to purchase shares. It is easy to see we will see a update on which direction they will move forward. You don’t come up with 3 positive Covid vaccines, then sit back and do nothing. He either is negotiations with Big Pharma or he will announce live testing. Either announcement will send stock into the big leagues. 12.5 or 13 cents and people are worried to purchase with big news coming. Last time went to 33 cent on a 2 trial approval. That is almost 300 percent. This will exceed 33 cents on a announcement.
  • Y
    YOUR DAD
    Vaxil Bio’s ImMucin is a Novel Neoantigen With Significant Anticancer Potential
    Immunotherapy is intended to train and harness the body’s own immune system in order to recognize and target disease. Many approved immunotherapies are quickly becoming physicians best hope in the battle against cancer. While chemotherapy was once thought to be a breakthrough, immunotherapies have come to the forefront due to the targeted efficacy and less systemic side effects of these powerful medications.

    One company pioneering new breakthroughs in cancer immunotherapy is Vaxil Bio Ltd (VXL.V). Vaxil was founded by Weizmann Institute scientists, one of Israel’s top research universities, in order to provide an altogether novel approach to cancer immunotherapy. The company has diligently advanced its immunotherapy platform and published its research and clinical results in top medical journals. Below is an introduction to Vaxil, its VaxHit™ technology, and ImMucin™, the company’s lead pipeline candidate for hematological malignancies and solid epithelial tumors.

    An Introduction To Vaxil Bio

    Vaxil is an immunotherapy company developing a pipeline of novel therapeutic vaccines and antibodies for the treatment of cancer. The company’s lead development candidate is ImMucin™, a therapeutic cancer vaccine comprised of the signal peptide domain of the MUC1 tumor-associated antigen (TAA). Vaxil has shown that ImMucin possesses a high density of T- and B-cell epitopes while preserving MUC1 specificity (1). MUC1 (mucin 1) is a cell surface glycoprotein that is highly expressed by carcinomas and hematological tumors, including multiple myeloma (2). Recently, Vaxil has shown that ImMucin can potentially have strong anti-tumor activity when used in combination with checkpoint inhibitors. Additionally, ImMucin represents a new class of neoantigens, with the potential to strongly stimulate the body’s immune system (3).

    Vaxil has completed an initial Phase 1/2 clinical trial (n=15) with ImMucin demonstrating the vaccine to be safe and highly tolerable in patients with multiple myeloma (MM). A robust immune response was seen in all patients treated with ImMucin, with the majority of patients achieving stable disease (4). A Phase 2 program is expected to commence in 2017 with ImMucin in a selected population of multiple myeloma patients. ImMucin was granted an Orphan Drug status for use in Multiple Myeloma in the U.S and the EU in 2015

    VaxHit™ Platform Technology

    ImMucin was discovered using Vaxil’s proprietary VaxHit platform technology. VaxHit combines algorithms which enable in-silico identification of signal peptides domains and their subsequent use as immunotherapeutic products. It is essentially a launchpad for unique and specific targeted immunotherapy products. VaxHit provides the ability to identify and select sequences within existing antigens with the potential to elicit a response in T-Cells, including CD4+ helper T-cells and CD8+ Killer T-cells, and in B-cell producing antibodies.

    Importantly, during the antigen selection process, Vaxil scientists look for antigens that are highly expressed on tumor cells but less so on healthy cells.. The immune activation by the selected peptide sequence should be robust and impact both cellular and humoral immunity.. The use of signal peptides hold the promise of creating “universal” immunotherapies that target multiple patient populations and are less restricted to certain HLA subtypes.

    Target Selection – MUC1

    The target antigen for Vaxil’s lead development program, ImMucin, is MUC1. MUC1 is an oncogenic transmembrane glycoprotein in the mucin family found to be overexpressed in a wide variety of hematologic malignancies and solid tumors. For example, it is overexpressed in more than 90% of breast cancers (5) with clear differentiation between normal and malignant cells (6). Work out of Dana-Farber Cancer Institute / Harvard Medical School shows that blocking MUC1 induces death in breast cancer cells in vitro and in xenograft models (7). Implications of MUC1 aberrant expression have also been linked to lung cancers (8) and multiple myeloma (9).

    With respect to multiple myeloma (MM), researchers out of Dana-Farber / Harvard demonstrated that MUC1 silencing by CRISPR editing results in downregulation of MYC messenger RNA and protein. The MYC oncoprotein is critical for MM cell and primary tumor survival. Studies further show that MUC1 levels positively correlate with MM progression and in primary cells from over 800 multiple myeloma patients. The findings are published in Blood (May 2016) and collectively provide convincing evidence that MUC1-C drives MYC expression in MM (10).
  • l
    lennard
    Vaxil...A biotech with all the goods and no marketing strategy. The proof is reflected in the sp. The only strategy that is making sense is they are trying to get rid of retail investors by holding back the data so their friends can buy in.
  • l
    lennard
    Trump is promoting the Regeneron drug he took for Covid19 . He says he will make it available for free. Goren can can withhold all his data forever now. Probably put it in the attic to collect dust while Regeneron reaps the reward. Trump keeps mentioning several companies for vaccines that have failed but Goren feels it is best to fly under the radar and hide from the world. One word from Trump about Vaxil and this stock would fly but according to the gospel of Goren we keep all data to ourselves. You are seeing his failed strategy reflected in the sp.
  • S
    Sammy Z
    VXL.V VXL.F Valix Bio is the only company that never rushed their Covid Vaccine, to get to the live trails. They developed 3 different Covid 19 Vaccines, they tests on animals all were successful. They went back to work on more data, and work out any kinks, before they begin live testing on humans. They will make a announce on their live testing any day now, watch out this stock will sky rocket. They will win the Covid Vaccine race, just like they are winning the TB vaccine, oncology cancer race, now passed/successfully in various stages. With Vaxil Bio working on 3 cures, with top ranked Israel research University, this investment at this low price is a no brainier. I am sure Big Pharma who have all failed, offering Vaxil Millions to join forces. Like I stated they will win the race to a safe Covid 19 Vaccine, along with their TB Vaccine, Oncology cancer cures that has received a FDA orphan approval.
  • S
    Sammy Z
    There is a big reason 1.5 million shares traded today with no news.
  • Y
    YOUR DAD
    Is there any news ?
  • S
    Sammy Z
    Watch for another major announcement soon, people really missed the value of this latest partnership and importance of Development of this drug. Look for a live trial announcement really soon for their Covid Vaccine.
  • S
    Sammy Z
    $VXL.V VXLF VAXIL BIO who recently had produce 3 Covid vaccine that were successful on mice, is about to make a major announcement. A lot of volume the last 3 days. Look for a announcement for human injections or a major partnership with big Pharma. Either way this stock about to take off. They are also in multiple stages for a TB Vaccine, as well in stage 2 of a Oncology cancer cell development. They already received a FDA orphan drug approval. With multiple new developments to be announced on not just one drug this is a must investment. Currently they are working with one of the best Research Universities in Israel.
  • L
    Licusloly
    Yeah, I had a thought like that, Israel gives the vaccine they say they are recovered. Vxllf is praised at the press conference its repeated all over the worlds press, shares go up to 1000 were all millionaires and happily ever after. 🤪
  • T
    TED
    Look at IPA ,AUP and TRIL, bought for pennies. Look at prices today!!!!!!
    Not all are going to succeed, but if you are investing based on blind greed without supporting companies that are honourable invest somewhere else.
  • S
    Sammy Z
    Something is up with Vaxil. Canada gave millions of dollars yesterday to multi groups developing a vaccine. On a list of approval a month ago was vaxil that applied. Stock is moving up, with positive results on the testing on animals, we should hear about live testing soon.
  • S
    Sam
    If the update is coming late October it better be ground shattering. The opportunity window is closing.
  • l
    lennard
    If this is true I wonder if Vaxil is the one. Big pharma has surpressed many cures with cancer being one among them. It is alleged a cure will be announced soon.
  • w
    william
    The drug they are giving the President is to build up his cell, it is the same type of drug Vaxil is working on. Oncology Cancer Cell, Vaxil has successful received a FDA partial approval. Vaxil has 3 Covid Vaccine they have recently tested, they were successful with their trail in animals. The Covid Vaccine is taken to prevent you from getting thenVirus. What they gave the President is building up his cell to fight the virus. Vaxil successfully has developed a prevent drug, along with a cell build up to fight the virus, if it has entered your system. Vaxil Bio stock will explode very soon.
  • w
    william
    I was told on Friday, we would be hearing update a soon. They should announce live trials or partnership with Big pharma that has failed with side effects for their Vaccine.
  • S
    Sammy Z
    $VXL.V VXL.F Vaxil Bio who recently successfully had 3 Covid Vaccines pass all test, last week. Look like a major announcement is coming. Stock has major volume and up 10 percent, someone knows something. We are expecting a press releases on a major company partnering or announcement of live testing starting. Anyone one of these announcements will send the stock to new highs.
  • F
    FIRST
    News must be coming.
  • S
    Sammy Z
    Israel holidays end today look for a announcement early next week. A lot of volume this week, I am sure we will have very positive come out.